Donglin Wang

机构：China Geological Survey, Chongqing Cancer Hospital · ORCID：0000-0002-6897-2696

发表论文 165 篇 · 总被引 2405 次 · h-index 26

代表论文

• Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 63)
• Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE) (2024 · Journal of Thoracic Oncology · 被引 40)
• Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study (2023 · BMC Medicine · 被引 13)
• Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia (2023 · Immunotherapy · 被引 11)
• HIF1α and HIF2α regulate non-small-cell lung cancer dedifferentiation via expression of Sox2 and Oct4 under hypoxic conditions (2023 · Gene · 被引 10)
• Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies (2023 · Lung Cancer · 被引 7)